Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in LondonGlobeNewsWire • Wednesday
New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic CardiomyopathyGlobeNewsWire • Monday
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/05/26
Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical UpdatesGlobeNewsWire • 11/05/26
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewsWire • 10/29/26
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic CardiomyopathyGlobeNewsWire • 10/23/26
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular DiseaseGlobeNewsWire • 10/21/26
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And MoreSeeking Alpha • 09/30/26
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayBenzinga • 09/28/26
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/09/26
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor ConferencesGlobeNewsWire • 09/01/26
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart FailureGlobeNewsWire • 08/31/26
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851GlobeNewsWire • 08/24/26
Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage AssetsSeeking Alpha • 08/19/26
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/06/26
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical UpdatesGlobeNewsWire • 08/06/26
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026GlobeNewsWire • 07/30/26
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)GlobeNewsWire • 07/27/26